Skip to main content

Table 1 Study design and patient characteristics of 12 studies of bDMARDs in PsA reporting WPAI outcomes

From: Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis

Study name, year, and NCT

Study design, country

Intervention

Study sample size, n

Age (years), mean (SD)

Male, %

Disease duration (years), mean (SD)

Biologic experience, %

Employed, %

Psoriasis, %

PASI, mean (SD)

DAS28-CRP, mean (SD)

WPAI version

KEEPsAKE 1 2022 (NCT03675308) [23]

RCT, Multiple

Risankizumab 150 mg

483

51.3 (12.2)

52.2

7.1 (7.0)

0

–a

100

10.9 (10.1)

–

WPAI:PsA

Placebo

481

51.2 (12.1)

48.6

7.1 (7.7)

0

100

10.0 (10.4)

–

KEEPsAKE 2 2022 (NCT03671148) [24]

RCT, Multiple

Risankizumab 150 mg

224

53.1 (12.5)

44.6

8.2 (8.2)

46.9

–a

54.9b

7.7 (6.7)

–

WPAI:PsA

Placebo

219

52.7 (12.6)

45.2

8.2 (8.3)

46.1

54.3b

8.4 (9.9)

–

BE OPTIMAL 2022 (NCT03895203) [25] (data on file)

RCT, Multiple

Bimekizumab 160 mg

431

48.5 (12.6)

46.6

6.0 (7.3)

0

63

50.3b

8.2 (6.8)

3.8 (0.9)

WPAI:SHP

Adalimumab 40 mg

140

49.0 (12.8)

50.7

6.1 (6.8)

0

64

48.6b

8.6 (7.6)

3.7 (0.9)

Placeboe

281

48.7 (11.7)

45.2

5.6 (6.5)

0

67

49.8b

7.9 (5.6)

3.8 (1.0)

SELECT-PsA 1 2021 (NCT03104400) [22]

RCT, Multiple

Upadacitinib 15 mg QD

429

51.6 (12.2)

44.5

6.2 (7.4)

0

58a

–

9.8 (10.0)

–

WPAI

Adalimumab 40 mg EOW

429

51.4 (12.0)

48.2

5.9 (7.1)

0

–

9.4 (8.5)

–

Placebo

423

50.4 (12.2)

51.1

6.2 (7.0)

0

–

11.2 (11.4)

–

DISCOVER-2 2021 (NCT03158285) [26]

RCT, Multiple

Guselkumab 100 mg Q4W

245

46.0 (12.0)

58.0

5.5 (5.9)

0

62

100

10.8 (11.7)

–

WPAI:PsA

Guselkumab 100 mg Q8W

248

45.0 (12.0)

52.0

5.1 (5.5)

0

100

9.7 (11.7)

–

Placebo

246

46.0 (12.0)

48.0

5.8 (5.6)

–

100

9.3 (9.8)

–

SELECT-PsA 2 2021 (NCT03104374) [27]

RCT, Multiple

Upadacitinib 15 mg QD

211

53.0 (12.0)

46.4

9.6 (8.4)

100

–a

–

10.1 (9.2)

–

WPAI

Placebo

212

54.1 (11.5)

43.4

11.0 (10.3)

100

–

11.7 (11.4)

–

FUTURE 1 2017 (NCT01392326) [28]

RCT, Multiple

Secukinumab 150 mg Q4W

202

49.6 (11.8)

47.5

–

29.2c

51

53.5b

15.6 (13.9)

4.8 (1.1)

WPAI:GH

Placebo

202

48.5 (11.2)

47.5

–

61

54.0b

15.1 (11.6)

4.9 (1.1)

SPIRIT-P2 2017 (NCT02349295) [29, 30]

RCT, Multiple

Ixekizumab 80 mg Q4W

122

52.6 (13.6)

52.0

11 (9.6)

100

53

97.0d

6.4 (7.9)

5.1 (1.1)

WPAI:SHP

Ixekizumab 80 mg Q2W

123

51.7 (11.9)

41.0

9.9 (7.4)

100

57

92.0d

6.2 (8.7)

5.1 (1.1)

Placebo

118

51.5 (10.4)

47.0

9.2 (7.3)

100

44.9

–

5.2 (6.3)

5.0 (1.1)

SPIRIT-P1 2018 (NCT01695239) [29, 31]

RCT, Multiple

Adalimumab 40 mg Q2W

101

48.6 (12.4)

50.5

6.9 (7.5)

0

61

96.0d

5.5 (6.5)

4.9 (1.0)

WPAI:SHP

Ixekizumab 80 mg Q4W

107

49.1 (10.1)

42.1

6.2 (6.4)

0

68

93.5d

6.9 (6.6)

5.0 (1.0)

Ixekizumab 80 mg Q2W

103

49.8 (12.6)

46.6

7.2 (8.0)

0

60

92.2d

6.0 (7.0)

5.0 (1.0)

Placebo

106

50.6 (12.3)

45.3

6.3 (6.9)

0

45.3

–

6.2 (7.5)

4.9 (1.0)

FUTURE 2 2015 (NCT01752634) [32]

RCT, Multiple

Secukinumab 300 mg Q4W

100

46.9 (12.6)

51.0

7.4 (7.5)

33.0c

–a

41.0b

11.9 (8.4)b

4.8 (1.1)

WPAI:GH

Secukinumab 150 mg Q4W

100

46.5 (11.7)

55.0

6.5 (8.2)

37.0c

58.0b

16.2 (14.3)b

4.9 (1.1)

Placebo

98

49.9 (12.5)

39.8

7.3 (7.8)

35.7c

43.9b

11.6 (8.3)

4.7 (1.0)

Nakagawa 2019 (NCT02414633) [33]

Prospective observational, Japan

Adalimumab 40 mg, 80 mg

106

49.3 (10.7)

72.6

–

10.4

100

–

9.0 (8.6)

3.8 (1.3)

WPAI:PsA v2

Corrona 2020 (NCT02530268) [21]

Prospective observational, United States

Secukinumab 150 mg, 300 mg

100

51.6 (11.6)

54.3

7.0 (7.0)

83.0

–

–

–

–

WPAI

  1. Only studies with data available at baseline and 24 weeks are included in this table
  2. bDMARD, biologic disease-modifying anti-rheumatic drug; DAS28-CRP, Disease Activity Score 28-joint count using C reactive protein; EOW, every other week; GH, general health; PsA, psoriatic arthritis; PASI, Psoriatic Arthritis Severity Index; Q2W, every 2 weeks; Q4W, every 4 weeks; Q8W, every 8 weeks; QD, daily; RCT, randomized controlled trial; SD, standard deviation; SHP, Specific Health Problem; TNFi, tumour necrosis factor inhibitor; WPAI, Work Productivity and Activity Impairment
  3. aStudy only reports that patients employed at baseline were evaluated for all domains except activity impairment
  4. bPsoriasis affecting ≥ 3% of body surface area
  5. cDefined as previous number of TNFi
  6. dCurrent psoriasis at baseline
  7. ePlacebo patients switched to intervention at 16 weeks
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us